Table 2

Risk of malignant tumours in men up to age 99 after a histopathological verified diagnosis of gynecomastia 1970–79. Follow up time includes 1970–1999 (8375.2 years). The cohort consists of 446 men.
Diagnosis
OBS
 EXP
 SIR
 95% Confidence
 interval
140–209
 All malignant tumours
 68
 66.07
 1.03
 0.80
 1.30
140
      Lip
 1
 0.70
 1.43
 0.04
 7.97
141_3_4
 Oral cavity
 0
 0.51
 0.00
 0.00
 7.18
142
      Parotid glands
 0
 0.19
 0.00
 0.00
 19.71
145–148
 Pharynx, hypopharynx
 0
 0.42
 0.00
 0.00
 8.69
150
      Esophagus
 3
 0.78
 3.82
 0.79
 11.17
151
      Stomach
 3
 4.09
 0.73
 0.15
 2.15
153
      Colon
 7
 5.43
 1.29
 0.52
 2.66
154
      Rectum
 0
 3.57
 0.00
 0.00
 1.03
1550
 Liver and intrahepatic ducts
 1
 0.94
 1.06
 0.03
 5.90
1551–1559
 Gallblader & bile ducts
 1
 0.67
 1.50
 0.04
 8.34
157
      Pancreas
 1
 1.95
 0.51
 0.01
 2.86
160
      Nasal cavities & sinus
 0
 0.13
 0.00
 0.00
 27.71
161
      Larynx
 0
 0.65
 0.00
 0.00
 5.67
1620–1621
 Trachea & lung
 6
 6.31
 0.95
 0.35
 2.07
1622
 Mesothelioma
 0
 0.31
 0.00
 0.00
 12.04
170
      Male breast cancer
 0
 0.09
 0.00
 0.00
 42.96
177
      Prostate
 16
 16.21
 0.99
 0.56
 1.60
178
      Testicle
 3
 0.52
 5.82
 1.20
 17.00
180
      Kidney
 1
 2.18
 0.46
 0.01
 2.55
181
      Urinary bl,.urinary tc.
 1
 4.85
 0.21
 0.01
 1.15
190
      Melanoma
 0
 1.73
 0.00
 0.00
 2.1
191
      Skin excl melanoma
 13
 4.06
 3.21
 1.71
 5.48
193
      Brain & nervous system
 1
 1.71
 0.59
 0.01
 3.26
194
      Thyroid
 0
 0.30
 0.00
 0.00
 12.43
196–197
 Bone & soft tissue
 0
 0.49
 0.00
 0.00
 7.59
200+202
 Non-Hodgkin's lymphoma
 1
 1.96
 0.51
 0.01
 2.84
201
      Hodgkin's disease
 0
 0.28
 0.00
 0.00
 12.97
203
      Multiple myeloma
 0
 0.90
 0.00
 0.00
 4.11
Acute leukemia
 1
 0.54
 1.86
 0.05
 10.38
204.1
      Chr. lymph. leukemia
 0
 0.74
 0.00
 0.00
 4.98
205.1
      Chr myeloid leukemia
 0
 0.18
 0.00
 0.00
 20.83
208
      Polycythemia vera
 0
 0.17
 0.00
 0.00
 21.67

Olsson et al. BMC Cancer 2002 2:26   doi:10.1186/1471-2407-2-26